Mental Health

Whether they saw patients in an office or virtually, doctors prescribed medication for attention deficit hyperactivity disorder at similar rates, according to an analysis by Epic Research.

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.

TimelyCare, a virtual care company focused on higher education, offers counseling and behavioral health services around the clock.

Researchers found that some patients had a higher no-show rate for virtual appointments than those with office visits.

Mental health issues have impacted minorities and at-risk groups the highest. But a new analysis has found that disparities exist within at-risk populations.

Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.

This is the fourth indication for Vraylar, a dopamine and serotonin partial agonist that can now be used as an adjunctive therapy in patients with major depressive disorder.

Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.

University of Arkansas researchers added to the understanding of how anxiety affects sleep with research that looked for associations between anxiety and bedtime procrastination and other patterns of poor sleep.

EmpiRx Health CEO Karthik Ganesh discusses how the PBM was able to decrease mental health drug spending at a time when utilization is increasing.

Aripiprazole, currently available as a once-monthly injection under the brand name Abilify Maintena, is being reviewed as a two-month therapy. The FDA target date for completion of the review is April 27, 2023.

Axsome anticipates Auvelity to be commercially available in the fourth quarter of 2022.

A clinical trial showed Dyanavel XR tablets were bioequivalent to the extended-release oral suspension formulation of Dyanavel.

A recent issue brief from the Kaiser Family Foundation says anxiety and depression, drug overdose deaths, self-harm and eating disorders have increased in adolescents as access and utilization of mental health care has declined.

Doug Nemecek, M.D., chief medical officer, behavioral health at Evernorth, talks about the mental health issues teenagers are facing.

The Psychopharmacologic Drugs Advisory Committee will meet on June 17, 2022; the PDUFA date is August 4, 2022.

Dr. Caroline Carney of Magellan Healthcare discusses the psychedelics in the pipeline for treating mental health conditions.

The new code will be effective April 1, 2022.

With a PDUFA date of Aug. 4, 2022, the FDA plans to hold an advisory committee meeting on resubmitted data for Nuplazid in patients with Alzheimer's disease who have psychosis.

Eprontia is the first liquid formulation of topiramate approved to both treat and prevent seizure.

ZIMHI is the second product approved by the FDA to counteract opioid, and it is a high-dose naloxone expected to be launched in the first quarter of 2022.

The FDA approved Lybalvi in June 2021 to treat schizophrenia and bipolar disorder.

Submission is based on extrapolation analysis and results examining the effects of Rexulti in treating symptoms of schizophrenia in patients 13 to 17 years old. The FDA is expected to complete its review in December 2021.

The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.

The Alzheimer's Association praises the approval but not the price tag. A Harvard Medical School professor who resigned from an FDA advisory committee says the OK "was probably the worst approval decision in recent U.S. history" in his resignation letter.